NCT03851887Unknown2 期
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC): A Prospective, Single-armed, Stage II Clinical Trial
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2018年12月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
To evaluate the efiicacy of TAI combine SBRT in unresectable HCC
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •older than 18 years old and younger than 75 years;
- •ECOG PS≤1;
- •proven advanced hepatocellular carcinoma according patological examination or EASL/AASLD diagnostic criteria;
- •not previous treated for tumor;
- •cannot accepted hepatectomy;
- •the lab test could meet:
- •neutrophil count≥2.0×109/L;
- •hemoglobin≥100g/L;
- •platelet count≥75×109/L;
- •serum albumin≥35g/L;
- •total bilirubin<2-times upper limit of normal;
- •ALT<3-times upper limit of normal;
- •AST<3-times upper limit of normal;
- •serum creatine<1.5-times upper limit of normal;
- •PT≤upper limit of normal plus 4 seconds;
- •sign up consent.
排除标准
- •cannot tolerate TAI or SBRT;
- •known history of other malignancy;
- •be allergic to related drugs;
- •underwent organ transplantation before;
- •be treated before (interferon included);
- •known history of HIV infection;
- •known history of drug or alcohol abuse;
- •have GI hemorrhage or cardiac/brain vascular events within 30 days;
- •pregnancy.
研究组 & 干预措施
treatment group
Experimental
TAI combine SBRT
干预措施: TAI combine SBRT (Combination Product)
结局指标
主要结局
PFS
时间窗: From date of randomization until the date of progression, assessed up to 36 months
progression-free survival
ORR
时间窗: From date of randomization until the date of death, assessed up to 36 months
objective response rate
次要结局
- OS(From date of randomization until the date of death from any cause, assessed up to 36 months)
- DCR(From date of randomization until the date of death, assessed up to 36 months)
研究者
Rong-ping Guo
Professor
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT03851939Sun Yat-sen University65
已完成
早期 1 期
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular CarcinomaHepatocellular Carcinoma (HCC)NCT01247298University of Alabama at Birmingham17
已完成
不适用
Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in ChinaCarcinoma, HepatocellularNCT01839630Bayer302
招募中
2 期
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical TrialHepatocellular CarcinomaNCT05751343Sun Yat-sen University55
Unknown
3 期
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT04053985Sun Yat-sen University206